Automated ADAMTS-13 Special coagulation analytics for HUS Diagnostic Center

The HUS Group requeted tenders for the following entity: The object of the procurement is the analytics for measuring the enzymatic activity of ADAMTS-13 as a random access-based definition. ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) cleaves the multimer structures of the von Willebrand factor. In thrombotic thrombocytopenic purpura (TTP), ADAMTS-13 activity has declined, leading to the formation of extra-large vWF multimer structures and to thrombosis complications. The patients are often critically ill and low ADAMTS-13 activity confirms the diagnosis. The fastest possible diagnostics is therefore needed. The random access method enables faster response times, which is a significant advantage especially in the clinical use of ADAMTS-13 measuring. An automated system also reduces the workload involved in these measurements. The products are described in more detail in in Appendix 1 to the invitation to tender (Price and product form). This is a total procurement, i.e. the procurement is not divided into lots because the procurement seeks a comprehensive solution for ADAMTS-13 coagulation analytics, including the device (one analyzer) and its maintenance and supplies. The reagents and other supplies required for the device shall be located in the consignment stock established by the selected tenderer in the Client’s service location. The procurement also includes an option for the additional procurement of one (1) Equipment including its maintenance, for example, if the production amounts increase during the contract period. These are the Client’s (HUS) options, i.e., the decision on using the options is made by the procurement entity. The studies mentioned in this call for tenders will be carried out by the HUS Group. The analytics will be performed in the coagulation laboratory of the automated laboratory in the HUSLAB Building. The ADAMTS-13 samples usually arrive one by one and are analyzed on a daily basis. The controls at both levels are usually analyzed once on the days on which the sample is analyzed. Therefore, in practice, the definition of one sample always uses the reagent to the amount required for the sample and two controls. In 2024, a total of 370 P -ADAM13 studies were carried out at HUS Diagnostic Center. The Client already uses the existing equipment it has purchased (Acustar Bio-Flash equipment, 2 pcs) to perform the studies. If the offered tests can be performed using the Client’s own existing equipment, the use of this equipment can be continued until the end of its life cycle. In this case, an order for the new device may not necessarily be placed during the contract period concluded on the basis of this competitive tendering process. The decision on placing the order is made by the Client. If the Client does not have existing equipment of its own for performing the offered tests, the order for a new device will be made after the procurement decision. The scope of the procurement also includes (all) device-specific consumables related to the products offered, which are needed in the intended use of the device, as well as complementary products to the devices. Required consumables are indicated/announced in Appendix 1. In addition, during the contract period, products belonging to the categories of products covered by the contract and not specified in the product appendix (see procurement contract) can also be procured in accordance with the estimated value of the procurement. In addition, we requested pricing for a maintenance contract for the analyzer. After the period of warranty of the new device has ended, the Client decides what level of maintenance it will use. The Client shall decide on the conclusion of the possible maintenance contract separately. The validity of the post-warranty maintenance contract for the equipment begins when the contract has been signed and will continue one year at a time, unless either party gives notice of terminating the contract. The consumption estimates stated in the call for tenders and its appendices are estimates based on the previous volumes of tests performed at HUS Diagnostic Center, and the contracting entity does not commit to the reported amounts of euros or the consumption estimates. The actual ordered quantities might be larger or smaller than the ones stated here. The object of the procurement and the requirements pertaining to it are described in detail in the call for tenders and its appendices.Main features of the procedureThe procurement shall comply with the Act on Public Procurement and Concession Contracts (1397/2016, referred to as the Public Procurement Act). The procurement value exceeds the EU threshold value. The procedure shall be an open procedure as defined in section 32 of the Public Procurement Act. PROCESSING OF TENDERS The procedure shall include the following phases: Contracting entity 1. Opens the tenders 2. Verifies the suitability of the tenderer 3. Checks that the tenders conform to the invitation to tender 4. Compares the tenders and possible trial use 5. Requests and checks certificates and reports on the suitability of the winning tenderer(s) 6. Makes a procurement decision and communicates it to all the tenderers 7. Concludes an agreement with the selected tenderer(s) LANGUAGE OF THE COMPETITIVE TENDERING PROCEDURE The procurement documents are available in English. If a tenderer needs the documents in another language, the tenderer shall be responsible for translation and liable for the associated costs. Tenders must be prepared in English. PARALLEL TENDERS Parallel tenders are not permitted. PARTIAL TENDERS Partial tenders will not be accepted.